CUMBERLAND PHARMACEUTICALS INC

Cumberland Pharmaceuticals Inc. (CPIX) has announced top-line results from its Phase 2a ASSIST-SSc trial, which evaluated the use of oral ifetroban in patients diagnosed with systemic sclerosis. The trial's outcomes indicate that ifetroban is safe and well-tolerated within this specific patient group suffering from the rare disease. Further details are available in the press release furnished as Exhibit 99.1.

Cumberland Pharmaceuticals completed a strategic transaction with Apotex Inc. on July 1, 2026, divesting its FDA-approved products and certain equity interests for $100 million cash. This divestment led to a significant shift in the company's focus towards its proprietary pipeline, particularly ifetroban. For the second quarter of 2026, the company reported a net loss attributable to common shareholders of $(4.28) million, compared to a net loss of $(0.74) million in Q2 2025. Net revenues from continuing operations were $166,458 for the quarter.

Cumberland Pharmaceuticals Inc. announced its Q2 2026 financial results and provided a company update following the successful closing of a strategic transaction. The company divested its portfolio of FDA-approved brands and commercial organization to Apotex Health for $100 million in cash, plus an additional $11 million. This transaction enabled Cumberland to return capital to shareholders through a special cash dividend of $1.50 per share and transition into a development-stage biopharmaceutical company. For Q2 2026, the company reported a net loss from continuing operations of $3.1 million and a total net loss of $4.1 million.

Cumberland Pharmaceuticals Inc. declared a special cash dividend of $1.50 per share, payable around July 31, 2026, to shareholders of record on July 23, 2026. This decision follows a strategic transaction with Apotex Health Corp., which provided $100 million in cash and up to $11 million in additional payments, resulting in greater net cash than originally projected. The Board also authorized a new $5 million open-market share repurchase program, replacing the previous one with $2.1 million remaining, and several Board members plan to increase their holdings. The company will now focus on developing its ifetroban product candidates.

Cumberland Pharmaceuticals completed the sale of its branded pharmaceutical assets to Apotex for $100 million in cash, following shareholder approval. This strategic divestment strengthens Cumberland's financial position, enabling it to repay a $5.3 million loan and focus resources on its rare disease pipeline, including ifetroban clinical programs. The transaction also involves the transfer of certain personnel to Apotex.

Cumberland Pharmaceuticals announced a strategic transaction to divest its portfolio of FDA-approved brands to Apotex Inc. for $100 million in cash, aiming to sharpen its focus on developing high-value product candidates. For the first quarter of 2026, the company reported net revenues of $9.1 million and a net loss of $3.3 million. Additionally, Cumberland provided updates on its development pipeline, including breakthrough Phase II results for ifetroban in Duchenne muscular dystrophy and FDA Fast Track Designation for the candidate.

Cumberland Pharmaceuticals Inc. has entered into a strategic transaction to integrate its commercial products with an affiliate of Apotex Inc. Apotex will acquire several FDA-approved products, including Acetadote and Caldolor, for $100 million. Cumberland will retain its Cumberland Emerging Technologies assets and ifetroban product candidates, intending to focus on their development. The deal, unanimously approved by Cumberland's board, is subject to shareholder approval and other customary closing conditions.